Analysis of anti-inflammatory enantiomers by HPLC in human plasma and urine: A review

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2012, Pages 96-112

  Carlucci, Giuseppe ^a   Carlucci, Maura ^a   Locatelli, Marcello ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Biological fluids; Enantiomers; HPLC; NSAIDs

Indexed keywords

ETODOLAC; FENOPROFEN; FLURBIPROFEN; FURPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; TIAPROFENIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN;

ANALGESIC ACTIVITY; ANALYTIC METHOD; ANKYLOSING SPONDYLITIS; BODY FLUID; CARBON NUCLEAR MAGNETIC RESONANCE; CHRONIC PAIN; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; ENANTIOMER; GOUT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; PAIN; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOM;

EID: 84867495586     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/187152312803476228     Document Type: Review

References (160)

1. Vane, J. R, Bakhle, Y. S, Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol, 1998, 38, 97-120.
2. Bhushan, R, Martens, J. Resolution of enantiomers of ibuprofen byliquid chromatography: A review. Biomed. Chromatogr, 1998, 12, 309-316.
3. Han, S. M. Direct enantiomeric separations by high-performanceliquid chromatography using cyclodextrins. Biomed. Chromatogr, 1997, 11, 259-271.
4. Ye, J, Yu, W, Chen, G, Shen, Z, Zeng, S. Enantiomeric separa-tion of 2-arypropionic acid nonsteroidal anti-inflammatory drugs by HPLC with hydroxypropyl-betacyclodextrin as chiral mobile phase additive. Biomed. Chromatogr, 2010, 24, 799-807.
5. Sultan, M, Stecher, G, Stöggl, W. M, Barkry, R, Zaborski, P, Huck, C. W, El Kousy, N. M, Bonn, G. K. Sample pre-treatment and determination of non steroidal anti-inflammatory drugs (NSAIDs) in pharmaceutical formulations and biological samples (blood, plasma, erythrocytes) by HPLC-UV-MS and micro-HPLC. Curr. Med. Chem, 2005, 12, 573-588.
6. Busson, M. Update on ibuprofen: Review article. J. Int. Med. Res, 1986, 14, 53-62.
7. Nicoll-Griffith, D. A. Streoeletctronic model to explain the resolu-tion of enantiomeric ibuprofen amides on the Pirkle chiral stationary phase. J. Chromatogr. 1987, 402, 179-187.
8. Jamali, F, Singh, N. N, Pasutto, F. M, Russell, A. S, Coutts, R. T. Pharmacokinetics of ibuprofen enantiomers in humans following oral administration of tablets with different absorption rates. Pharm. Res, 1988, 5, 40-43.
9. Adams, S. S, Bresloff, P, Mason, C. G. Pharmacological differencesbetween the optical isomers of ibuprofen: Evidence for metabolic inversion of the (-)-isomer. J. Pharm. Pharmacol, 1976, 28, 256-257.
10. Lee, E. J. D, Williams, K. M, Grahm, G. G, Day, R. O, Champion, G. D. Liquid chromatographic determination and plasma concentration profile of optical isomers of ibuprofen in humans. J. Pharm. Sci, 1984, 73, 1542-1544.
11. Maître, J. M, Boss, G, Testa, B. High-performance liquid chroma-tographic separation of the enantiomers of anti-inflammatory 2arylpropionates: suitability of the method for in vitro metabolic studies. J. Chromatogr, 1984, 299, 397-403.
12. Mehvar, R; Jamali, F, Pasutto, F. M. Liquid chromatographic assay ofibuprofen enantiomers in plasma. Clin. Chem, 1988, 34, 493-496.
13. Nicoll-Griffith, D. A, Inaba, T, Tang, B. K, Kalow, W. Method todetermine the enantiomers of ibuprofen from human urine by high-performance liquid chromatography. J. Chromatogr. Biomed. Appl, 1988, 72, 103-112.
14. Lau, Y. Y. Determination of ibuprofen enantiomers in humanplasma by derivatization and HPLC with fluorescence detection. J. Liq. Chromatogr. Rel. Technol, 1996, 19, 2143-2153.
15. Pettersson, K. J, Olsson, A. Liquid chromatographic determinationof the enantiomers of ibuprofen in plasma using a chiral AGP column. J. Chromatogr, 1991, 563, 414-418.
16. Lemko, C. H, Caillé, G, Foster, R. T. Stereospecific high-performance liquid chromatographic assay of ibuprofen: Improved sensitivity and sample processing efficiency. J. Chromatogr. Biomed. Appl, 1993, 619, 330-335.
17. De Vries, J. X, Schmitz-Kummer, E, Simeon, D. The analysis ofibuprofen enantiomers in human plasma and urine by HPLC on an 1-acid glycoprotein chiral stationary phase. J. Liq. Chromatogr, 1994, 17, 2127-2145.
18. Naidong, W, Lee, J. W. Development and validation of a liquidchromatographic method for the quantitation of ibuprofen enantiomers in human plasma. J. Pharm. Biomed. Anal, 1994, 12, 551-556.
19. Péhourcq, F, Lagrange, F, Labat, L, Bannwart, B. Simultaneousmeasurement of flurbirpofen, ibuprofen and ketoprofen enantiomer concentration in plasma using L-leucinamide as the chiral coupling component. J. Liq. Chromatogr, 1995, 18, 3969-3879.
20. Ikegawa, S, Murao, N, Oohashi, J, Goto, J. Separatory determi-nation of diastereomeric ibuprofen glucuronides in human urine by liquid chromatography/electrospray Ionization-mass spectrometry. Biomed. Chromatogr, 1998, 12, 317-321.
21. Canaparo, R, Muntoni, E, Zara, G. P, Della Pepa, C, Berno, E, Costa, M, Eandi, M. Determination of ibuprofen in human plasma by highperformance liquid chromatography: Validation and application in pharmacokinetic study. Biomed. Chromatogr, 2000, 14, 219-226.
22. Tan, S. C, Jackson, S. H. D, Swift, C. G, Hutt, A. J, Enantio-specific analysis of ibuprofen by high-performance liquid chromatography: Determination of free and total drug enantiomer concentrations in serum and urine. Chromatographia, 1997, 46, 23-32.
23. Teng, X. W, Wang, S. W. J, Davies, N. M. Stereospecific high-performance liquid chromatographic analysis of ibuprofen in rat serum. J. Chromatogr. B, 2003, 796, 225-231.
24. Ye J, Yu W, Chen, G, Shen, Z, Zeng, S. Enantiomeric separationof 2-arylpropionic acid nonsteroidal anti-inflammatory drugs by HLPC with hydroxipropyl--cyclodextrin as chiral mobile phase additive. Biomed. Chromatogr, 2010, 24, 799-807.
25. Jamali, F, Broks, D. R. Clinical pharmacokinetics of ketoprofenand its enantiomers. Clin. Pharmacokinet, 1990, 19, 197-217.
26. Castro, E, Soraci, A, Fogel, F, Tapia, O. Chiral inversion of R(-)fenoprofen and ketoprofen enantiomers in cats. J. Vet. Pharmacol. Ther, 2000, 26, 29-37.
27. Igarza, L, Soraci, A, Auza, N, Zeballos, H. Chiral inversion of(R)-ketoprofen: influence of age differing physiological status in dairy cattle. Vet. Res. Commun, 2002, 26, 29-37.
28. Aberg, G, Ciofalo, V. B, Pendleton, R. G, Ray, G. Inversion of (R) to(S)-ketoprofen in eight animal species. Chirality, 1995, 7, 383-387.
29. Farinotti, R, Mahuzier, G. High-performance liquid chroma-tographic determination of ketoprofen in blood and urine. J. Pharm. Sci, 1979, 68, 484-485.
30. Bannier, A, Brazier, J. L, Ribon, B, Quincy, C. Determination ofketoprofen in biological fluids by reversed-phase chromatography. J. Pharm. Sci, 1980, 69, 763-765.
31. Kaye, C. M, Sankey, M. G, Holt, J. E. A high-pressure liquid chro-matographic method for the assay of ketoprofen in plasma and urine, and its application to determining the urinary excretion of Orudis to man. Br. J. Clin. Pharm, 1981, 11, 395-398.
32. Oka, K, Aoshima, S. Highly sensitive determination of ketoprofenin human serum and urine and its application to pharmacokinetic study. J. Chromatogr, 1985, 34, 419-424.
33. Royer, R. J, Lapique, F, Netter, P, Monot, C, Bannwarth B. Es-timation of high-performance liquid chromatography of ketoprofen in plasma. Application to the study of its protein binding. Biomed. Pharmacother, 1986, 40, 100-105.
34. Owen S. G, Koberts, M. S, Friesen, W. T. Rapid high-performanceliquid chromatographic analysis for the simultaneous analysis of non steroidal anti-inflammatory. J. Chromatogr, 1987, 416, 293-302.
35. Lempläinen, M, Mäkelä, A. L. Determination of ketoprofen by high-performance liquid chromatography from serum and urine. Clinicalapplication from serum and urine in children with juvenile rheuma with hydroxypropyl-cyclodextrin as mobile phase additive. J. toid arthritis. Int. J. Clin. Pharmacol. Res, 1987, 7, 265-271.
36. Sallustio, B. C, Abas, A, Hayball, P. J-; Purdie, Y. J, Meffin, P. J. Enantiospecific high-performance liquid chromatographic analysis of 2-aryl propionic acids, ketoprofen and fenoprofen. J. Chromatogr, 1986, 374, 329-337.
37. Iwakawa, S, He, X, Hashimoto, S, Volland, C, Benet, L. Z, Lin, E. T. Stereoselective disposition of ketoprofen in rats. Drug Metabol. Dispos, 1991, 19, 717-718.
38. Wright, M. R, Jamali, F. Limited extent of stereochemical conver-sion of chiral non-steroidal anti-inflammatory drugs induced by derivatization methods employing ethyl chloroformate. J. Chromatogr, 1993, 616, 59-65.
39. Fukushima, T, Santa, T, Homma, H, Al-Kindy, S. M, Imai, K. Enantiomeric separation and detection of 2-arylpropionic acids derivatized with (N, N-dimethylamine)sulphonyl benzofuran reagents on a modified cellulose stationary phase by high-performance liquid chromatography. Anal. Chem, 1997, 69, 1793-1799.
40. Panus, P. C, Tober-Meyer, B, Ferslew, K. E. Tissue extraction andhigh-performance liquid chromatography determination of ketoprofen enantiomers. J. Chromatogr. B, 1998, 705, 295-302.
41. Aboul-Emein, H. Y, Overbe V. A, Vander Weken, G, Baeyens, W, Oda, H, Deprez, P, Kruif, A. D. High-perfromance liquid chromatography on Chiracel OJ-R for enantiomer separation and analysis of ketoprofen, from horse plasma, as the 9-amino phenanthrene derivative. J. Pharm. Pharmacol, 1998, 50, 291-296.
42. Carr, R. A, Caillé, G, Ngoc, A. H, Foster, R. T. Stereospecifichigh-performance liquid chromatographic assay of ketoprofen in human plasma and urine. J. Chromatogr. B, 1995, 668, 175-181.
43. Overbeke, A. V, Baeyens, W, Oda, H, Aboul-Enein, H. Y. Directenantiomeric high-performance liquid chromatography separation of several 2-aryl propionic acids, barbituric acids and benzodiazepenes on Chiralcel OJ-R chiral stationary phase. Chromatographia, 1996, 43, 599-606.
44. Oi, N, Kitahara, H, Aoki, F, Kisu, N. Ditect separation of car-boxylic acid enantiomers by high-performance liquid chromatography with amide and urea derivatives bonded to silica gel as chiral stationary phases. J. Chromatogr, 1995, 689, 195-201.
45. Grubb, N. G, Rudy, D. W, Hall, S. D. Stereoselective high-performance liquid chromatographic analysis of ketoprofen and its acyl glucuronides in chronic renal insufficiency. J. Chromatogr. B, 1996, 678, 237-244.
46. Boisvert, J, Caillé, G, McGilveay, I. J, Qureshi, S. A. Quantifica-tion of ketoprofen enantiomers in human plasma based on solidphase extraction and enantioselective column chromatography. J. Chromatogr. B, 1997, 690, 189-193.
47. Hoke, S. H, Pinkston, J. D, Bailey, R. E, Tanguay, S. L, Eichold, T. H. Comparison of packed-column supercritical fluid chromatography-tandem mass spectrometry with liquid chromatographytandem mass spectrometry for bioanalytical determination of (R) and (S)-ketoprofen in human plasma following automated 96-well solid phase extraction. Anal. Chem, 2000, 72, 4235-4241.
48. Lovlin, R, Vakilj, M, Jamali, F. Rapid, sensitive and direct chiralHPLC method for ketoprofen enantiomers. J. Chromatogr. B, 1996, 679, 196-198.
49. Björkman S. Determination of the enantiomers of ketoprofen inblood plasma by ion-pair extraction and high-performance liquid chromatography of leucinamide derivatives. J. Chromatogr, 1987, 414, 465-471.
50. Foster, R. T, Jamali, F. High-performance liquid chromatographicassay of ketoprofen enantiomers in human plasma and urine. J. Chromatogr, 1987, 416, 388-393.
51. Yagi, M, Shibukawa, A, Nakagawa, T. Direct injection analysisof ketoprofen enantiomers in plasma using column switching highperformance liquid chromatography system. Chem. Pharm. Bull, 1990, 38, 2513-2517.
52. Menzel-Soglowek, S, Geisslinger, G, Brune, K. Stereoselectivehigh-performance liquid chromatographic determination of ketoprofen, ibuprofen and fenoprofen in plasma using a chiral 1-acid glycoprotein column. J. Chromatogr, 1990, 532, 295-303.
53. Hayball, P. J, Nation, R. L, Bochner, F, Le Leu, R. K. Enantio-specific analysis of ketoprofen in plasma by high-performance liquid chromatography. J. Chromatogr, 1991, 570, 446-452.
54. Ameyibor, E, Stewart, J. T. HPLC determination of ketoprofenenantiomers in human serum using octadecylsilane 1, 5 μm column Pharm. Biomed. Anal, 1998, 17, 83-88.
55. Hutt, A. J, Caldwell, J. The importance of stereochemistry in theclinical pharmacokinetics of the 2-arylpropionic acid non steroidal anti-inflammatory drugs. Clin. Pharmacokinet. 1984, 9, 371-373.
56. Evans, A. M. Enantioselective pharmakodinamics and pharmacoki-netics of chiral non-steroidal anti-inflammatory drugs. Eur. J. Clin. Pharmacol, 1992, 42, 237-256.
57. Jamali, F, Mehvar, R, Pasutto, F. M. Enantioselective aspects ofdrug action and disposition: therapeutic pitfall. J. Pharm. Sci, 1989, 79, 695-715.
58. Brune, K, Beck, W. S, Geisslinger, G. Aspirin-like drugs mayblock pain independently of prostaglandin synthesis inhibition. Experientia, 1991, 47, 257-260.
59. Jamali, F, Berry, B. W, Tehrani, M. R. Stereoselective pharma-cokinetics of flurbiprofen in humans and rats. J. Pharm. Sci, 1988, 77, 666-669.
60. Knadler, M. P, Brater, D. C, Hall, S. D. Stereoselective dispositionof flurbiprofen in normal volunteers. Br. J. Clin. Pharmacol, 1991, 33, 369-376.
61. Johnson, V. A, Wilson, J. T. Flurbiprofen analysis in plasma andbreast milk by high-performance liquid chromatography. J. Chromatogr, 1986, 382, 367-371.
62. Adams W. J, Bothwell, B. E, Bothwell, W. M. Simultaneous deter-mination of flurbiprofen and its major metabolite on physiological fluids using liquid chromatography with fluorescence detection. Anal. Chem, 1987, 59, 1504-1509.
63. Babhair, S. A. Determination of flurbiprofen in dosage form andbiological fluids by high-performance liquid chromatography. J. Liq. Chromatogr, 1988, 11, 463-473.
64. Allenmark, S, Andersson, S. Optical resolution of some biologi-cally active compounds by chiral liquid chromatography on BSAsilica columns. Chirality, 1989, 1, 154-160.
65. Nocter, T. A, Felix, G, Wainer, I. W. Stereochemical resolution ofenantiomeric 2-arylpropionic acid non-steroidal antiinflammatory drugs on a human serum albumin based high-performance liquid chromatographic chiral stationary phase. Chromatographia, 1991, 13, 55-59.
66. Snider, B. G, Beaubien, L. J, Sears, D. J. Determination of flur-biprofen and ibuprofen in dog serum with automated sample preparation. J. Pharm. Sci, 1981, 70, 1347-1349.
67. Albert, K. S, Gillespie, W. R, Raabe, A. Determination of flur-biprofen in human serum by reverse-phase high-performance liquid chromatography with fluorescence detection. J. Pharm. Sci, 1984, 73, 1823-1827.
68. Hutzler, J. M, Frye, R. F, Tracy, T. S. Sensitive and specific high-performance liquid chromatographic assay for 4'hydroxyflurbiprofen and flurbiprofen in human urine and plasma. J. Chromatogr. B, 2000, 749, 119-125.
69. Knadler, M. P, Hall, S. D. High-performance liquid chroma-tographic analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine. J. Chromatogr, 1989, 494, 173-182.
70. Geisslinger, G, Menzel-Soglowek, S, Schuster, O, Brune, K. Stereoselective High-performance liquid chromatographic determination of flurbiprofen in human plasma. J. Chromatogr, 1992, 573, 163-167.
71. Van Overbeke, A, Baryens, W, Van Den Bossche, W, Dewaele, C. Enantiomeric separation of amide derivatives of some 2arylpropionic acids by HPLC on a cellulose-based chiral stationary phase. J. Pharm. Biomed. Anal, 1994, 12, 911-916.
72. Péhourcq, F, Jarry, C, Bannwarth, B, Chiral resolution of flur-biprofen and ketoprofen enantiomers by HPLC on a glycopeptidestype column chiral stationary phase. Biomed. Chromatogr, 2001, 15, 217-222.
73. Teng, X. W, Wang, S. W. J, Davies, N. M. Stereospecific high-performance liquid chromatographic analysis of flurbiprofen in rat serum. J. Chromatogr, 2003, 796, 225-231.
74. Péhuorcq, F, Matoga, M, Jarry, C, Bannwarth, B. HPLC mi-crodetermination of flurbiprofen enantiomers in plasma with a glycopeptides-type chiral stationary phase column. Biomed. Chromatogr, 2004, 18, 330-334.
75. Jin, Y. X, Tang, Y. H, Zeng, S. Analysis of flurbiprofen, ketopro-fen and etodolac enantiomers by pre-column derivatization RPHPLC and application to drug-protein binding in human plasma. J. Pharm. Biomed. Anal, 2008, 46, 953-958.
76. Naidong, W, Lee, J. W. Development and validation of a liquidchromatographic method for the quantitation of ibuprofen enantiomers in human plasma. J. Pharm. Biomed. Anal, 1994, 12, 551-556.
77. Tan, S. C, Jackson, S. H. D, Swift, C. G, Hutt, A. J. Enantiospecificanalysis of ibuprofen by high-performance liquid chromatography: Determination of free and total drug enantiomer concentrations in serum and urine. Chromatographia, 1997, 46, 23-32.
78. Tomlinson, R. W, Ringold, H. G, Quereschi, M. C. Relationshipbetween inhibition of prostaglandin synthesis and drug efficacy: Support for the current theory on mode of action of aspirin-like drugs. Biochem. Biophys. Res. Commun, 1972, 46, 552-559.
79. Brogden, P. N, Pinder, R. M, Sawyer, P. R. Naproxen: A review ofits pharmacological properties and therapeutic efficacy and use. Drugs, 1975, 9, 326-363.
80. Brogden, P. N, Heel, R. C, Speight, T. M. Naproxen up to date: Areview of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs, 1979, 18, 241-277.
81. Mortensen, A, Biørn Jensen, E, Bernth-Peterson, P. The determi-nation of naproxen by spectrofluorometry and its binding to serum proteins. Acta Pharmacol. Toxicol, 1979, 44, 277-283.
82. Pini, L. A, Bertolotti, M, Trenti, T. Disposition of naproxen afteroral administration during and between migraine attacks. Headache, 1993, 33, 191-194.
83. Evans, A. M, Enantioselective pharmacodynamic and pharmacoki-netics of chiral non-steroidal anti-inflammatory drug. Eur. J. Clin. Pharmacol, 1992, 42, 237-256.
84. Desager, J. P, Vanderbist, M, Harvengt, C. Naproxen plasmalevels in volunteers after a single-dose administration by oral and rectal routes. J. Clin. Pharmacol, 1976, 16, 189-193.
85. Todd, P. A, Clissod, S. P. Naproxen. A reappraisal of its pharma-cology and its therapeutic use in rheumatic diseases and pain states. Drugs, 1990, 40, 91-137.
86. Anttila, M. Fluorimetric determination of naproxen in serum. J. Pharm. Sci, 1977, 66, 433-434.
87. Anttila, M, Haataja, M, Kasamsen, A. Pharmacokinetics ofnaproxen in subject with normal and impaired renal function. Eur. J. Cli. Pharmac, 1980, 18, 263-268.
88. Gøtzesche, P. C, Marinelli, K, Gyldin, -Sabroe, J P, Larssen, N. E, Sørensen, K. Bioavailability of naproxen tablets and suppositories in steady state. Scand. J. Rheumatol, 1983, 50, 1-9.
89. Larssen, N. E, Marinelli, K. Mass fragmentography quantificationof naproxen in human plasma. J. Chromatogr, 1981, 222, 482-485.
90. Shimek, J. L, Rao, N. G. S, Wahba Khalil, S. K, An isocratic high-pressure liquid chromatographic determination of naproxen and desmethylnaproxen in human plasma. J. Pharm. Sci, 1982, 71, 436-438.
91. Upton, R. A, Buskin, J. N, Guerntert, T. W, Williams, R. L, Riegelman, S. Convenient and sensitive high-performance liquid chromatography assay for ketoprofen, naproxen and other allied drugs in plasma and urine. J. Chromatogr, 1980, 190, 119-128.
92. Vree, T. B, Biggerlaar-Martea, M, Verweyva Wissen, C. P. W. G. M. Determination of naproxen, its metabolite Odesmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient HPLC analysis. J. Chromatogr. Biomed. Appl, 1992, 578, 239-249.
93. Faed, M. Properties of acyl glucuronides: Implications for studiesof the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev, 1984, 15, 1213-1249.
94. Foster, R. T, Jamali, F. High-performance liquid chromatographicassay of ketoprofen enantiomers in human plasma and urine. J. Chromatogr. 1987, 416, 388-393.
95. Rubin, A, Knadler, M. P, Ho, P. P. K, Bechtol, L. D, Wolen, R. L. Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans. J. Pharm. Sci, 1985, 74, 82-84.
96. Blagbrough, I. S, Daykin, M. M, Doherty, M, Pattrick, M, Shaw, P. N. High-performance liquid chromatographic determination of naproxen, ibuprofen and diclofenac in plasma and synovial fluid in man. J. Chromatogr, 1992, 578, 251-257.
97. Goto, M. E, Ohno, T, Matsumoto, H. Nishida, M. Simultaneousanalysis of naproxen, nabumetone and its major metabolite 6methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography. J. Pharm. Biomed. Anal, 2000, 23, 917-925.
98. Andersen, J. V, Hansen, S. H. Simultaneous determination of (R)-and (S) naproxen and (R) and (S)-6-O-desmethylnaproxen byhigh-performance liquid chromatography on a Chiral-AGP column. J. Chromatogr, 1992, 577, 362-365.
99. Rooks, W. H, Tolomonis, A. J, Maloney, P. J, Wallach, M. B, Schuler, M. E. The analgesic and anti-inflammatory profile of (±)-5benzoyl-1, 2-dihydro-3H-pyrrol [1, 2a]pyrrole-1-carboxylic acid (RS-37619). Agents Actions, 1982, 12, 684-690.
100. Buckley, M. M, Brogdon, R. N. Ketorolac: A review of its pharma-codynamic and pharmacokinetic properties and therapeutic potential. Drugs, 1990, 39, 86-109.
101. Litvak, K. M, McEvoy, G. K. Ketorolac, an injectable nonnaroticanalgesic. Clin. Pharm, 1990, 9, 921-935.
102. Mroszczak, E, Lee, F, Combs, D, Sarnquist, F, Huang, B, Wu, A. Keterolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab. Dispos, 1987, 15, 518-526.
103. Jamali, F. Pharmacokinetics of enantiomers of chiral non-steroidalanti-inflammatory drugs. Eur. J. Drug Metab. Pharmacokinet, 1988, 19, 957-967.
104. Hayball, P. J, Tamblyn, J. G, Holden, Y, Wrobel, J. Stereoselec-tive analysis of ketorolac in human plasma by high-performance liquid chromatography. Chirality, 1993, 5, 31-35.
105. Mills, M. H, Mather, L. E, Gu, X. S, Huang, J. L. Determination ofketorolac enantiomers in plasma using enantioselective liquid chromatography on an 1-acid glycoprotein chiral stationary phase and ultraviolet detection. J. Chromatogr. Biomed. Appl, 1994, 658, 177-182.
106. Jones, D. J, Bjorksten, A. R. Detection of ketorolac enantiomers inhuman plasma using enantioselective liquid chromatography. J. Chromatogr. Biomed. Appl, 1994, 661, 165-167.
107. Tsina, I, Tam, Y. L, Rocha, C, Massey, I, Tarnowski, T. Anindirect (derivatization) and a direct HPLC method for the determination of the enantiomers of ketorolac in plasma. J. Pharm. Biomed. Anal, 1996, 15, 403-417.
108. Kauffman, R. E, Lieh-Lai, M. W, Uy, H. G, Aravind, M. K. Enanti-omerselective pharmacokinetics and metabolism of ketorolac in children. Clin. Pharmacol. Ther, 1999, 65, 382-388.
109. Vakily, M, Corrigan, B, Jamali, F. The problem of racemisation inthe stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. Pharm. Res, 1995, 12, 1652-1657.
110. Sorkin, E. M; Brodgen, R. N. Tiaprofenic acid: A review of itspharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs, 1985, 29, 208-235.
111. Plosker, G. L, Wagstaff, A. J. Tiaprofenic acid: A reappraisal of itspharmacological properties and use in the management of rheumatic diseases. Drugs, 1995, 50, 1050-1075.
112. Hutt, A. J, Caldwell, J. The metabolic chiral inversion of 2-arypropionic acids: a novel route with pharmacological consequences. J. Phar. Pharmacol, 1983, 35, 693-704.
113. Caldwell, J, Hutt, A. J, Fournel-Gilleux, S. The metabolic chiralinversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem. Pharmacol, 1988, 37, 105-114.
114. Brugger, R, Reichel, C, Brune, K, Geisslinger, G. Molecularpharmacological characterization of key enzymes involved in the R/S-inversion of ibuprofen. Exp. Toxic. Pathol, 1996, 48, 40-46.
115. Nakamura, Y, Yamaguchi, T, Takahashi, S, Hashimoto, S, Iwa-tani, K, Nakagawa, Y. Optical isomerisation mechanism of R-(-) hydrotropic acid derivatives. J. Pharmacobiodyn, 1981, 4, s-1.
116. Hall, S. D, Xiaotao, O. The role of coenzyme A in the biotransfor-mation of 2-aryl propionic acids. Chem. Biol. Interact, 1994, 90, 235-251.
117. Menzel, S, Waibel, R, Brune, K, Geisslinger, G. Is the formationof R-ibuprofen-adenylate the first stereoselective Step of chiral inversion? Biochem. Pharmacol, 1994, 48, 1056-1058.
118. Shieh, W. R, Chen, C. S. Purification and characterization of novel"2-arylpropionyl-CoA epimerases" from rat liver cytosol and mitochondria. J. Biol. Chem, 1993, 50, 3487-3493.
119. Reichel, C, Bang, H, Geisslinger, G, Menzel, S. 2-arylpropionyl-CoA epimerase: Partial espied sequences and tissue localization. Biochem. Pharmacol, 1995, 50, 1803-1806.
120. Reichel, C, Brugger, R, Bang, H, Geisslinger, G, Brune, K. Molecular clonig and expression of a 2-arylpropionyl-CoA epimerase: a key enzyme of the inversion metabolism of ibuprofen. Mol. Pharmacol. 1997, 51, 576-582.
121. Tracy, T. S, Hall, S. D. Metabolic inversion of (R)-ibuprofen: Epi-merization and hydrolysis of ibuprofen-coenzyme A. Drug Met. Dispos, 1992, 20, 322-327.
122. King, J. N, Mauron, C, LeGoff, C, Hauffle, S. Bidirectional chiral inversion of the enantiomers of the non steroidal anti-inflammatorydrug oxindation in dogs. Chirality, 1994, 6, 460-466.
123. Mroszczak, E, Combs, D, Chaplin, M, Tsina, I, Tarnowski, T, Rocha, C, Tam, Y, Boyd, A, Young, J, Depass, L. Chiral kineticsand dynamics of keterolac. J. Clin. Pharmacol, 1996, 36, 521-539.
124. Mohamed, M. E, Abdel-Aziz, M. W, Gad-Kariem, E. R. Rapiddifferential pulse polarographic determination of tiaprofenic acid. J. Assoc. Off. Anal. Chem, 1984, 67, 634-638.
125. Pottier, J, Berlin, D, Raynaud, J. P. Pharmacokinetics of the antiinflammatory tiaprofenic acid in humans, mice, rats, rabbits anddogs. J. Pharm. Sci, 1977, 66, 1030-1036.
126. Singh, N. N, Pasutto, F. M, Coutts, R. T. Gas chromatographicseparation of optically active anti-inflammatory 2-aryl-rpopionic acids using (+)or (-)-amphetamine as derivatizating reagent. J. Chromatogr, 1986, 378, 125-135.
127. Mehvar, R, Jamali, F, Pasutto, F. M. Rapid and sensitive high-performance liquid chromatographic assay of tiaprofenic acid enantiomers in human plasma and urine. J. Chromatogr, 1988, 425, 135-142.
128. Muller, N, Lapique, F, Drelon, E, Gillet, P, Monot, C, Poletto, B, Netter, P. Direct high-performance liquid chromatographic resolution of the enantiomers of tiaprofenic acid using immobilized human serum albumin. J. Chromatogr, 1993, 616, 261-270.
129. Vakily, M, Jamali, F. Human pharmacokinetics of tiaprofenic acidafter regular and sustained release formulations: lack of chiral inversion and stereoselective release. J. Pharm. Sci, 1994, 83, 495-498.
130. Geisslinger, G, Menzel, S, Brune, K. Stereospecific determinationof tiaprofenic acid in plasma: problems with drug degradation. J. Chromatogr. B, 1996, 675, 77-81.
131. Sing, N. N, Jamali, F, Pasutto, F. M, Russell, A. S, Coutts, R. T, Drader, K. S. Pharmacokinetic of the enantiomers of tiaprofenic acid in humans. J. Pharm. Sci, 1986, 75, 439-442.
132. Pirkle, W. H, Welch, C. J. An improved chiral stationary phase forthe chromatographic separation of underivatized naproxen enantiomers. J. Liq. Chromatogr, 1992, 15, 1947-1955.
133. Okamoto Y, Aburatani, R, Kaida, Y. Direct chromatographicseparation of 2-arylpropionic acid enantiomers using tri(3, 5dimethylphenylcarbamate)s of cellulose and amylase as chiral stationary phases. Chirality, 1989, 1, 239-242.
134. Karger, A. E, Stoll, E, Hänsel, W. Direct chiral separation of ti-aprofen, carprofen and flurbiprofen by cyclodextrin-modified capillary electrophoresis. Pharmazie, 1994, 49, 155-159.
135. Jamali, F, Russell, A. S, Berry, B. W, Lehmann, C. High-performance liquid chromatographic analysis of tiaprofenic acid and its metabolites in plasma and urine by direct injection. J. Chromatogr, 1984, 310, 327-333.
136. Palumbo, G, Fanini, D, Pantaleoni, G. C, Carlucci, G. Pharmacol-ogical studies on furprofen: its pharmacokinetic profile and antiinflammatory action following oral administration. Int. J. Immunopath. Pharmacol, 1991, 4, 85-90.
137. Carlucci, G, Palumbo, G, Mazzeo, P. A high-performance liquidchromatographic procedure for the simultaneous determination of norfloxacin and furprofen in rat plasma. Biomed. Chromatogr, 1993, 7, 126-128.
138. Carlucci, G, Pantaleoni, G. C, Palumbo, G. Determination of fur-profen in human plasma by solid-phase extraction and reversed-phase high-performance liquid chromatography. J. Chromatogr, 1988, 424, 201-204.
139. Carlucci, G, Palumbo, G, Mazzeo, P. Indirect stereoselectivedetermination of enantiomers of furprofen in human plasma by high-performance liquid chromatography. Chromatographia, 1992, 34, 618-620.
140. Carlucci, G, Fanini, D, Palumbo, G. Quantitation of the enanti-omers of furprofen in biological fluids by High-Performance Liquid Chromatography. 2 Joint Meeting of Italian and Hungarian Pharmacological Societies-Budapest-1990, 51-52.
141. Rubin, A, Knadler, M. P, Ho, P. P. K, Bechtol, L. D, Wollen, R. L. Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans. J. Pharm. Sci, 1985, 74, 82-84.
142. Volland, C, Sun, H, Benet, L. Z. Stereoselective analysis of feno-profen and its metabolites. J. Chromatogr, 1990, 534, 127-138.
143. Mayer, J. M, Testa, B. Stereoselectivity in metabolic reactions of toxi-cation and detoxication. In: Welling P. G, Balant, L. P. editors. Pharmacokinetics of drugs. Berlin: Springer-Verlag, 1994, p 209-231.
144. Tucker, G. T, Lennard, M. S. Enantiomer specific pharmacokinet-ics. Pharmacol. Ther, 1990, 45, 309-329.
145. Volland, C, Sun, H, Dammeyer, J, Benet, L. Z. Stereoselectivedegradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to protein plasma. Drug Met. Dispos, 1991, 19, 1080-1086.
146. Day, R. O, McLachlan, A. J, Graham, G. G, Williams, K. M. Phar-macokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clin. Pharmacokinet, 1999, 36, 191-210.
147. Barissa, G. R, Poggi, J. C, Donadi, E. A, Dos Reis M. L, Lan-chote, V. L. Influence of rheumatoid arthritis in the enantioselective disposition of fenoprofen. Chirality, 2004, 16, 602-608.
148. De Miranda Silva, C, Marques, M. P, Barissa, G. R, Donati, E. A, Da Silva, L. M, Lanchote, V. L. Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis. Chirality, 2007, 19, 255-263.
149. Boni, J. P, Korth-Braddley, J. M, Martin, P, Simcoe, D. K, Rich-ards, L. S, Rennebohm, R, Walson, P. D. Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis. Clin. Ther, 1999, 21, 1715-24.
150. Jones, R. A. Etodolac: An overview of a selective COX-2 inhibitor. Inflammopharmacol, 1999, 7, 269-75.
151. Balfour, J. A, Buckley, M. M, Etodolac A reappraisal of its phar-macology and therapeutic use in rheumatic diseases and pain states. Drugs, 1991, 42, 274-99.
152. Berendes, U, Blaschke, G. Simultaneous determination of thephase II metabolites of the non steroidal anti-inflammatory drug etodolac in human urine. Enantiomer, 1996, 1, 415-22.
153. Becker-Scharfenkamp U, Blaschke, G. Evaluation of the stereose-lective metabolism of the chiral analgesic drug etodolac by highperformance liquid chromatography. J. Chromatogr, 1993, 621, 199-07.
154. Jamali, F, Mehvar, R, Lemko, C, Eradiri, O. Application of astereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans. J. Pharm. Sci, 1988, 77, 963-66.
155. Caccamese, S. Direct high-performance liquid chromatography(HPLC) separation of etodolac enantiomers using chiral stationary phases. Chirality, 1993, 5, 164-67.
156. Brocks, D. R, Jamali, F, Russell, A. S. Stereoselective dispositionof etodolac enantiomers in synovial fluid. J. Clin. Pharmacol, 1991, 31, 741-46.
157. Strikmann, D. B, Blaschke, G. Capillary electrochromatography-electrospray ionization mass spectrometry for the qualitative investigation of the drug etodolac and its metabolites in biological samples. J. Chromatogr. B, 2000, 748, 213-219.
158. Cosyns, L, Spain, M, Kraml, M. Sensitive high-performanceliquid chromatographic method for the determination of etodolac in serum. J. Pharm. Sci, 1983, 72, 275-77.
159. Strickmann, D. B, Blaschke, G. Isolation of an unknown metaboliteof the non-steroidal anti-inflammatory drug etodolac and its identification as 5-hydroxy etodolac. J. Pharm. Biomed. Anal, 2001, 25, 977-84.
160. Lee, H. S, Kang, I. M, Lee, H. W, Seo, J. H, Ryu, J. H, Choi, S. J, Lee, M. J, Jeong, S. Y, Cho, Y. W, Lee, K. T. Development and validation of a high performance liquid chromatography-tandem mass spectrometry for the determination of etodolac in human plasma. J. Chromatogr. B, 2008, 863, 158-62.